Tag Archives: ypsomed

Ypsomed Builds US Manufacturing Site; Eccogene Eyes Hong Kong IPO; Former Novo CEO Joins Healthcare Denmark

Three cardiometabolic-related news items have been observed: Ypsomed announced an investment of $248M for a US manufacturing site (view press release); Eccogene filed an IPO on the Hong Kong Stock Exchange (view article; view prospectus); and Lars Fruergaard Jørgensen was appointed Chair of Healthcare Denmark (view LinkedIn post; view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ESC 2025: Novo, Roche/Alnylam, and AstraZeneca Present New Data; Medtronic Closes in on Abbott CGM Launch; Ionis Topline Ph3 Olezarsen Results; NMPA Accepts Hengrui’s Obesity Application; Ypsomed’s SmartPilot Receives 510(k) Clearance; Biophytis Ph2 BIO101 Obesity Study; Skye Completes Ph2 Nimacimab Dosing

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Medtronic, Roche/Alnylam, AstraZeneca, Ionis Pharmaceuticals, Jiangsu Hengrui, Ypsomed, Biophytis, and Skye Bioscience. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Noom to Sell “Microdoses” of Wegovy; Sanofi Initiates Ph3 Tzield Study; MetaVia Partners for TA Discovery; Ypsomed Completes Sale of Diabetes Care Business

A series of cardiometabolic-related news items has been observed from Noom, Sanofi, MetaVia, and Ypsomed. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Tandem to Integrate with Abbott’s Glucose-Ketone Sensor; Insulet iOS App Integrates with Dexcom; Ypsomed and CamDiab Expand mylife Loop iOS; BI/Echosens Expand Partnership in MASH; Altimmune Initiates New Ph2 Study in ALD

A series of cardiometabolic-related news items has been observed from Tandem Diabetes Care/Abbott, Insulet/Dexcom, Ypsomed/CamDiab, Boehringer Ingelheim/Echosens, and Altimmune. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Files HD Oral Sema; Roche Expands US Manufacturing; MetaVia Additional Ph1 Obesity Results; Ypsomed Sells Diabetes Care Business; Biolinq $100M Series C; April CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Roche, MetaVia, Ypsomed, Biolinq, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Initiates Ph3 Tirzepatide T1DM Study; AOMs Left Out of Medicare Coverage; Ypsomed and Sidekick Partner for Obesity; GLP-1 Scientists Win Breakthrough Prize

A series of cardiometabolic new items has been observed from Lilly, CMS, Ypsomed/Sidekick Health, and Breakthrough Prize Foundation. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

CMS Price Negotiation Update; Ypsomed and CamDiab Launch mylife Loop on iOS

Two cardiometabolic-related news items have been observed: all 15 drug manufacturers agreed to participate in the second round CMS pricing negotiations (view press release) and Ypsomed and CamDiab launched mylife Loop on iOS systems (view press release).

This content is for Read Less members only.

Already a member? Log in here

Lexicon Strategic Update; Boston MASH Investor Event; Ypsomed to Manufacture Cagrisema Pens; Pep2Tango Obesity Startup; Generic Byetta FDA Approval

A series of cardiometabolic-related news items have been observed from Lexicon Pharmaceuticals, Boston Pharmaceuticals, Ypsomed, Versant Ventures, and Amneal Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Kerendia FINEARTS-HF Topline Results; Simplera CGM Approved by FDA; Novo Initiates Second Ph3 H2H Cagrisema vs. Tirzepatide T2DM Study; Ypsomed and MTD Complete BGM Business Sale

A series of cardiometabolic-related news items have been observed from Bayer, Medtronic, Novo Nordisk, and Ypsomed. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Omnipod 5 Launch Updates; Zealand Ph1b MAD Petrelintide data; Ypsomed AID Algorithm Approved by FDA; Silence Ph2 siRNA Results; Lilly Fights Compounded Tirzepatide Sales

A series of cardiometabolic-related news items have been observed from Insulet/Dexcom, Zealand, Ypsomed, Silence Therapeutics, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here